A

Almirall

Global biopharmaceutical company focused on dermatology

Global Market Insights Director

Full-Time
No salary listed
Expert
Bachelor's, Master's, MBA, PhD
Barcelona, Spain
In Person
Business & StrategyCorporate Strategy

About the job

Requirements
  • A bachelor's degree in Business Administration, Economics, Life Sciences, Data Science, Statistics, Engineering or a related field.
  • A minimum of 10–12 years of progressive experience in market insights, market research, forecasting, business analytics, competitive intelligence or strategic marketing within the pharmaceutical, biotechnology or closely related healthcare sector.
  • Proven experience leading a global or regional insights function and developing people in an international, matrix organisation.
  • Demonstrated mastery of primary and secondary research, forecasting, competitive intelligence, performance analytics and insight synthesis, with the judgement to select the right approach for the business question.
  • Strong pharmaceutical business acumen, including brand strategy, launches, lifecycle management, customer and patient dynamics, market access and the global-local operating model.
  • Experience influencing senior leaders and cross-functional teams through clear recommendations, constructive challenge and compelling executive communication.
  • Proven ability to manage multiple priorities, external partners and significant research or data investments with a focus on quality, impact and efficiency.
  • Fluent English, written and spoken, with the ability to operate effectively across cultures and geographies.
Responsibilities
  • Define an enterprise-wide global market insights vision, strategy, operating model, priorities and capability roadmap aligned with business and portfolio strategy.
  • Lead the Global Market Insights organisation by allocating resources, clarifying accountabilities and ensuring timely, high-quality delivery.
  • Partner with senior commercial, franchise, regional and functional leaders as a trusted strategic advisor; frame key decisions, challenge assumptions and provide an independent, evidence-based perspective.
  • Integrate customer, patient, market, competitor, sales, access and internal performance signals into a coherent narrative identifying opportunities, risks, drivers and implications.
  • Set standards for global market research planning, methodology, sampling, questionnaire design, synthesis and communication; oversee qualitative and quantitative studies.
  • Establish an ethical and compliant competitive and market intelligence cycle covering market evolution, competitor strategies, scientific and commercial developments and emerging disruptors.
  • Govern global forecasting frameworks, assumptions, scenarios and documentation across assets and markets, integrating market, epidemiology, access, competitive and performance perspectives.
  • Monitor sales, market share, customer and execution indicators; identify root causes and recommend actions to accelerate growth, improve launch readiness and optimise investment.
  • Provide insight leadership across lifecycle stages, including market opportunity assessment, indication and asset prioritisation, target product profile testing, demand and uptake scenarios, launch readiness and post-launch learning agendas.
  • Promote advanced analytics, automation and artificial intelligence for insight generation; partner on data quality and governance and ensure responsible, transparent and scalable innovation.
  • Establish concise dashboards, executive narratives and structured performance forums that communicate findings, implications, choices, risks and recommended actions.
  • Select and manage research, data and analytics partners; set quality expectations, prioritise spend, ensure procurement and compliance requirements and build internal capability where appropriate.
  • Coach, empower and retain the Global Market Insights team; build business acumen, consultative influence, methodological expertise and digital fluency; create succession and development plans.
  • Create feedback loops with regions and market companies, balancing global consistency with local relevance and enabling reuse of evidence, methods and learning.
  • Champion change and continuous improvement by simplifying ways of working and anticipating future capability needs while balancing urgent requirements with long-term value creation.
Desired Qualifications
  • An MBA, MSc, PhD or other relevant advanced degree.
  • Experience in both affiliate or regional roles and a global commercial organisation.
  • Experience in dermatology, immunology, specialty care and/or biologics, including launch and lifecycle insight needs.
  • Expertise integrating market research, claims or patient data, epidemiology, sales, digital engagement, customer relationship management and competitive intelligence into an unbiased, decision-ready perspective.
  • Knowledge of advanced analytics, data visualisation, automation and responsible artificial intelligence applications in commercial decision-making.
  • Strategic thinking, problem framing, synthesis, storytelling and executive presence.
  • People leadership that creates clarity, develops talent, delegates effectively, gives candid feedback and builds an inclusive, high-accountability culture.
  • Enterprise mindset and collaboration skills, with the confidence to influence without authority and reconcile different stakeholder perspectives.
  • Learning agility, curiosity, resilience and comfort operating in ambiguous, complex and fast-changing environments.
  • Working knowledge of global healthcare regulation, privacy, pharmacovigilance interfaces and applicable pharmaceutical industry codes relevant to market research and competitive intelligence.

About the company

Almirall develops and markets medicines for dermatological conditions, such as psoriasis, actinic keratosis, atopic dermatitis, and acne. Its products are created through R&D and partnerships, then manufactured and distributed across 100+ countries through global affiliates. The company differentiates itself with a long history (since 1944), an integrated global footprint (R&D center, plants, 15 affiliates), and a patient-centered approach that listens to needs. Its goal is to improve patients’ lives by providing dermatology-focused treatments and broad access to them.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Barcelona, Spain

Founded

1943

Get referred to Almirall

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 sales rose 7.5% to €602.7 million; EBITDA jumped 23.7%.
  • July 2026 Ebglyss sales surged 88.2% to €84.5 million, proving launch momentum.
  • July 2026 EMA filing acceptance for pediatric Ebglyss expands the franchise beyond adults.

What critics are saying

  • Ebglyss and Ilumetri still drive results; any launch stumble hits 2026-2030 growth.
  • China partnerships with Huaota, Certest, and CrystalO create IP, execution, and milestone complexity.
  • A weak first-half 2027 readout from Phase II assets would crush pipeline credibility.

What makes Almirall unique

  • Almirall runs a pure-play medical dermatology platform, with four PoC/Phase II programs in 2026.
  • August 2026 CrystalO deal extends Almirall’s China innovation funnel while keeping ex-China rights.
  • Ebglyss, Ilumetri, Wynzora, and Klisyri create a focused dermatology commercial base.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

10%

1 year growth

10%

2 year growth

10%
EuropaWire
Aug 11th, 2026
Almirall secures exclusive rights outside mainland China for CrystalO dermatology programme.

Almirall secures exclusive rights outside mainland China for CrystalO dermatology programme. (IN BRIEF) Almirall has entered into a collaboration and licensing agreement with CrystalO for the discovery and development of novel small molecules in medical dermatology. Under the agreement, CrystalO will handle candidate discovery, optimisation, IND-enabling studies and early clinical development, with the goal of achieving clinical proof of concept. Almirall will hold exclusive rights outside mainland China and will lead later-stage global development, manufacturing and commercialisation. The collaboration supports Almirall's strategy to strengthen its medical dermatology pipeline through external innovation, strategic partnerships and access to complementary R&D capabilities. (PRESS RELEASE) BARCELONA, 11-Aug-2026 - /EuropaWire/ - Almirall has entered into a collaboration and licensing agreement with CrystalO, a Chinese company focused on drug discovery, to identify and develop novel small molecules for use in medical dermatology. The partnership supports Almirall's broader innovation strategy, which includes identifying promising local research and development programmes that can complement the company's internal scientific capabilities. The agreement also reflects Almirall's continued focus on advancing differentiated treatments in dermatology, particularly in areas where patients continue to face significant unmet medical needs. Through strategic partnerships and scientific collaboration, Almirall aims to strengthen its pipeline and accelerate the development of new therapeutic options for skin conditions. Under the terms of the agreement, CrystalO will be responsible for candidate discovery, optimisation, IND-enabling studies and early clinical development. The objective is to advance selected candidates to clinical proof of concept. Almirall will hold exclusive rights outside mainland China. The company will also lead subsequent global development, manufacturing and commercialisation activities for the programme. Karl Ziegelbauer, Chief Scientific Officer at Almirall, said the collaboration with CrystalO represents another important step in advancing the company's innovation strategy in China. He said the agreement further strengthens Almirall's research and development pipeline in medical dermatology. Ziegelbauer added that Almirall sees potential in the discovery partnership to deliver meaningful benefits to patients living with skin conditions around the world. Dr Zhang Jin, Founder and Chief Executive Officer of CrystalO, said the company is honoured to enter into a strategic collaboration with Almirall, which he described as a leading company with a strong global reputation in dermatology. He said the partnership represents strong recognition of CrystalO's technology platform and its research and development capabilities in ion channel drug discovery. Dr Zhang added that CrystalO looks forward to working closely with Almirall, combining the strengths of both companies to accelerate the development of innovative medicines and bring benefits to patients worldwide as early as possible. Through the collaboration, Almirall is expanding its access to external innovation while strengthening its position in medical dermatology through a partnership focused on novel small molecules, ion channel drug discovery and global development opportunities. Media Contact: Media Relations Corporate Communications [email protected] T +34 932 91 35 08 MORE ON ALMIRALL, ETC.: EDITOR'S PICK:

The Pharma Letter
Aug 10th, 2026
Almirall strengthens China footprint with CrystalO collaboration.

Almirall strengthens China footprint with CrystalO collaboration. 10 August 2026 Spanish dermatology specialist Almirall (BME: ALM) today announced a collaboration and licensing agreement with Shenzhen CrystalO Biopharma Technology to jointly initiate an R&D collaboration for drug discovery in medical dermatology. The collaboration will combine CrystalO's scientific expertise in ion channels with Almirall's experience in medical dermatology research and clinical development to develop innovative drug candidates for skin diseases. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 24 July 2026 16 March 2026 11 October 2018 Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 10 August 2026 Company spotlight. A biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address highly prevalent diseases with limited treatment options. More features in pharmaceutical. 10 August 2026 9 August 2026

The Pharma Letter
Jul 25th, 2026
Almirall builds on biologics as first-half earnings climb.

Almirall builds on biologics as first-half earnings climb. 24 July 2026 Spanish medical dermatology company Almirall (BME: ALM) has reported first-half 2026 net sales of 602.7 million euros ($687.1 million), up 7.5% year on year, with profits rising far faster than the top line. Net income jumped 49.4% to 39.6 million euros, while core earnings, or EBITDA, climbed 23.7% to 150.7 million euros. Growth was led by the European dermatology business, where sales rose 18.1% to 341.9 million euros. The biologics portfolio did much of the heavy lifting. Atopic dermatitis treatment Ebglyss (lebrikizumab) nearly doubled to 84.5 million euros, up 88.2%, and plaque psoriasis drug Ilumetri (tildrakizumab) grew 10.5% to 125.2 million euros. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 20 July 2026 15 June 2026 11 May 2026 Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 24 July 2026 Company spotlight. A Santa Cruz, California-based biotechnology company developing orally delivered macrocyclic peptides that combine biologic-level potency with small-molecule drug-like properties to engage previously undruggable targets across cardiovascular and immunology. More features in pharmaceutical. 24 July 2026

Yahoo Finance
Jul 24th, 2026
Almirall H1 sales grow 7.5% to $675M, EBITDA rises 23.7% on dermatology strength

Almirall reported solid first-half 2026 results, with net sales growing 7.5% year-on-year to €602.7 million and EBITDA increasing 23.7% to €150.7 million. The Barcelona-based pharmaceutical company's European dermatology business drove growth, rising 18.1% to €341.9 million. The biologics portfolio performed strongly, with Ebglyss growing 88.2% to €84.5 million and Ilumetri increasing 10.5% to €125.2 million in net sales. Other products, including Wynzora and Klisyri, also showed positive performance. Almirall advanced its innovation strategy with four ongoing phase II studies and plans to initiate two additional studies by year-end. The company signed a research collaboration with Certest Biotec to develop treatments for rare dermatologic diseases. The company reiterated its full-year 2026 guidance of 9–12% growth and €270–290 million EBITDA.

Almirall
Jul 23rd, 2026
Almirall and Certest Biotec announce research collaboration and licensing agreement

Almirall and Certest Biotec announce research collaboration and licensing agreement Published on July 23, 2026